SEATTLE, Dec. 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced presentations or posters of interest related to Zevalin(R) (ibritumomab tiuxetan) to be presented at the 50th Annual Meeting of the American Society of Hematology (ASH), December 5-9, 2008 in San Francisco.
In addition, James Bianco, M.D., CEO of Cell Therapeutics will participate in a panel hosted by Biotechnology Industry Organization and Gerson Lehrman Group(R), "Gerson Lehrman Group Innovators: Non-Hodgkin's Lymphoma," on Saturday, December 6.
CTI and Spectrum announced on November 26, 2008 that they have entered into an agreement to form a joint venture, RIT Oncology LLC, to commercialize and develop Zevalin in the United States.
For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference Web site at http://www.hematology.org.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.
CONTACT: Media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
media@ctiseattle.com, or Investors, Ed Bell, +1-206-272-4345, or Lindsey
Jesch Logan, +1-206-272-4347, fax, +1-206-272-4434, invest@ctiseattle.com,
all of Cell Therapeutics, Inc.; or Medical Information, 1-800-715-0944,
info@askarm.com
Web site: http://www.celltherapeutics.com/
http://www.CellTherapeutics.com/press_room/
http://www.CellTherapeutics.com/investors/
